FOXO4

Quick Facts

Category: Senolytic / Cellular Senescence

Risk Level: High/Experimental

Research Status: Preclinical Experimental

Administration: Subcutaneous Injection

Typical Frequency: Every Other Day (Short Course)

Estimated Half-Life: Unknown

Primary Research Interest: Senescent Cell Clearance / Healthy Aging Research

Important Disclaimer

This material is provided strictly for educational and informational purposes related to experimental compounds and peptide research. FOXO4-DRI is not approved for general human use and remains an investigational compound supported primarily by preclinical research. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

1. Summary

FOXO4-DRI is an experimental senolytic peptide developed to selectively eliminate senescent cells by disrupting the interaction between the FOXO4 transcription factor and the tumor suppressor protein p53. The compound was designed to trigger apoptosis in dysfunctional senescent cells while preserving healthy neighboring cells.

Interest in FOXO4-DRI has centered on aging biology, regenerative medicine, and diseases associated with the accumulation of senescent cells. To date, published research has been limited to laboratory, cellular, and animal models, and no approved medical indication currently exists.

What People Commonly Claim

Reversal of biological aging
Removal of “zombie cells”
Improved longevity
Enhanced tissue regeneration
Improved physical function and vitality

What the Literature Actually Shows

FOXO4-DRI selectively induces apoptosis in senescent cells through disruption of the FOXO4-p53 interaction.
Animal studies have demonstrated improvements in tissue homeostasis following senescent cell clearance.
Independent studies have demonstrated senolytic activity in cartilage, vascular tissue, skin fibroblasts, and reproductive aging models.
No human clinical trials have established long-term safety or efficacy.
The compound remains an experimental research peptide without approved therapeutic use.

2. Reconstitution Guide

Vial Size: 10 mg
Dilutant Type: BAC Water
Amount of Dilutant Added: 1.5 mL
Final Concentration: 6.67 mg/mL

At this concentration:
• 2 mg = 0.30 mL (30 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

3. Route of Administration

FOXO4-DRI has most commonly been investigated in preclinical research as a subcutaneous injectable peptide.

Primary Route: SubQ Injection
Alternative Routes Discussed: None commonly referenced
Injection Timing Notes: Research protocols generally employ intermittent dosing schedules rather than continuous administration.

4. Common Research Protocols

Product Strength: 6.67 mg/mL
Typical Delivered Amount: 2 mg (0.30 mL / 30 units)
Frequency: Every Other Day
Cycle Length: Five consecutive doses followed by six months off
Special Notes: Published FOXO4-DRI research has focused primarily on short-duration senolytic treatment courses rather than chronic administration. Human dosing protocols have not been established, and community research protocols should not be considered clinically validated.

5. Mechanism of Action

FOXO4-DRI is a synthetic peptide designed to disrupt the interaction between FOXO4 and p53 within senescent cells. Under normal conditions, FOXO4 helps retain p53 within the nucleus of senescent cells, allowing those damaged cells to resist apoptosis.

By interfering with the FOXO4-p53 interaction, FOXO4-DRI permits p53 to relocate and activate apoptotic signaling pathways, leading to selective elimination of senescent cells. Preclinical studies have demonstrated reductions in senescent cell burden across multiple tissues, including connective tissue, vascular endothelium, cartilage, skin fibroblasts, and reproductive tissue.

6. Potential Benefits

Selective elimination of senescent cells
Potential improvement in tissue homeostasis
Reduced senescence-associated inflammatory signaling (SASP)
Potential improvement in vascular function
Potential improvement in cartilage health
Potential support for healthy reproductive aging
Potential improvement in tissue regeneration following senescent cell clearance
Support for healthy aging research

7. Potential Risks / Side Effects

High/Experimental

Injection site irritation
Localized inflammation
Immune system activation
Unknown long-term safety profile
Potential off-target apoptosis
Unknown effects on normal tissue remodeling
Potential effects on wound healing
Unknown consequences of repeated senescent cell depletion

8. Potential Benefits

Potential reduction of senescent-cell burden
Potential improvement in tissue homeostasis
Reduction of chronic inflammatory SASP signaling
Improved tissue function in multiple animal models
Potential support for healthy aging research
Improved physical function in preclinical studies
Potential benefits for fibrosis and age-related tissue dysfunction under experimental conditions

9. Potential Risks / Side Effects

High / Experimental

No established long-term human safety data
Unknown effects of repeated senescent-cell clearance
Potential disruption of beneficial transient senescent cells involved in wound healing
Unknown effects on normal tissue remodeling
Injection-site reactions
Potential immune or inflammatory responses
Unknown off-target effects
Experimental compound with limited clinical experience

10. Half-Life

The pharmacokinetic half-life of FOXO4-DRI has not been well established in published literature.

Most current research focuses on the biological effects of intermittent senescent-cell clearance rather than circulating peptide concentrations. Consequently, optimal dosing intervals and duration of activity remain areas of ongoing investigation.

11. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid repeated freeze-thaw cycles
Maintain sterile handling practices during preparation

12. Contraindications / Warnings

Not approved for routine clinical use
Pregnancy or breastfeeding
Active infection or acute illness
Recent major surgery or impaired wound healing
Active malignancy unless specifically studied under research protocols
Known hypersensitivity to peptide compounds

13. Further Study

14. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Peer-reviewed senescence biology literature
Cellular aging and longevity research
Preclinical senolytic peptide research
p53 and FOXO signaling pathway literature

15. Last Reviewed

July 2026